Expression of the mTOR pathway regulators in human pituitary adenomas indicates the clinical course

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3123-3132

  Jia, Wang ^a,b   Sanders, Andrew J ^b   Jia, Guijun ^a   Liu, Xiao ^a   Lu, Runchun ^a   Jiang, Wen G ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Invasion; mTOR; Pituitary adenoma; RAPTOR; RICTOR; Staging

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; RAPAMYCIN INDEPENDENT COMPANION OF MTOR; REGULATORY ASSOCIATED PROTEIN OF MTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CAVERNOUS SINUS; CONTROLLED STUDY; DISEASE COURSE; ENDOCRINE FUNCTION; FEMALE; GENETIC TRANSCRIPTION; GROWTH HORMONE SECRETING ADENOMA; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SELLA TURCICA; SIGNAL TRANSDUCTION; THYROTROPIN SECRETING ADENOMA; TUMOR INVASION;

INVASION; MTOR; PITUITARY ADENOMA; RAPTOR; RICTOR; STAGING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; CARRIER PROTEINS; CAVERNOUS SINUS; DISEASE PROGRESSION; ENDOCRINE SYSTEM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PITUITARY NEOPLASMS; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; TOR SERINE-THREONINE KINASES; TUMOR BURDEN;

EID: 84883272269     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ballou LM and Lin RZ: Rapamycin and mTOR kinase inhibitors. Journal of Chemical Biol 1: 27-36, 2008.
2. DeBerardinis RJ, Lum JJ, Hatzivassiliou G and Thompson CB: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20, 2008.
3. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P and Hall MN: Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol cell 10: 457-468, 2002.
4. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, Avruch J and Yonezawa K: The mammalian target of rapamycin (mTOR) partner, RAPTOR, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278: 15461-15464, 2003.
5. Dunlop EA and Tee AR: Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signall 21: 827-835, 2009.
6. Kaiser CA and Schekman R: Distinct sets of SEC genes govern transport vesicle formation and fusion early in the secretory pathway. Cell 61: 723-733, 1990.
7. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A and Hall MN: Mammalian TOR complex controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biology 6: 1122-1128, 2004.
8. Levy S, Avni D, Hariharan N, Perry RP and Meyuhas O: Oligopyrimidine tract at the 5' end of mammalian ribosomal protein mRNAs is required for their translational control. Proc Nati Acad Sci list 88: 3319-3323, 1991.
9. Meric-Bernstam F and Gonzalez-Angulo AM: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278-2287, 2009.
10. Lin TA, Kong X, Haystead TA, Pause A, Belsham G, Sonenberg N and Lawrence JC Jr.: PHAS-I as a link between mitogenactivated protein kinase and translation initiation. Science 266: 653-656, 1994.
11. Svitkin YV, Pause A, Haghighat A, Pyronnet S, Witherell G, Belsham GJ and Sonenberg N: The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure. RNA 7: 382-394, 2001.
12. Pickering BM and Willis AE: The implications of structured 5' untranslated regions on translation and disease. Semi Cell Develop Biol 16: 39-47, 2005.
13. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML and McCutcheon IE: The prevalence of pituitary adenomas: A systematic review. Cancer 101: 613-619, 2004.
14. Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H and Wang R: Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology 154: 1247-1259, 2013.
15. Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Goth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M and Grossman AB: Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocrine-related Cancer 16: 1329-1338, 2009.
16. Rubinfeld H and Shimon I: PI3K/AKT/mTOR and RAF/MEK/ERK signaling pathways perturbations in nonfunctioning pituitary adenomas. Endocrine 42: 285-291, 2012.
17. Sajjad EA, Zielinski G, Maksymowicz M, Hutnik L, Bednarczuk T and Wlodarski P: mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features. Endocrin Pathol 24: 11-19, 2013.
18. Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, and Shimon I: Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce antiproliferative effects in GHsecreting pituitary tumor cells in vitro. Endocrine-related Cancer 16: 1017-1027, 2009.
19. Sukumari-Ramesh S, Singh N, Dhandapani KM and Vender JR: mTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation. Surg Neurol Int 2: 22, 2011.
20. Wazir U, Newbold RF, Jiang WG, Sharma AK and Mokbel K: Prognostic and therapeutic implications of mTORC1 and RICTOR expression in human breast cancer. Oncol Rep 29: 1969-74, 2013.
21. Knosp E, Steiner E, Kitz K and Matula C: Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33: 610-617; discussion 617-618, 1993.
22. Hardy J: Transsphenoidal surgery of hypersecreting pituitary tumors. In: Diagnosis and Treatment of Pituitary Tumors, Kohler PO and Ross GT (eds.). Amsterdam, Exerpta Medica, pp: 179-198, 1973.
23. Laplante M and Sabatini DM: mTOR signaling at a glance. J Cell Sci 122: 3589-3594, 2009.
24. Lee M, Theodoropoulou M, Graw J, Roncaroli F, Zatelli MC and Pellegata NS: Levels of p27 sensitize to dual PI3K/mTOR inhibition. Mole Cancer Ther 10: 1450-1459, 2011.
25. Lu C, Willingham MC, Furuya F and Cheng SY: Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology 149: 3339-3345, 2008.
26. Dowling RJ, Topisirovic I, Fonseca BD, and Sonenberg N: Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 1804: 433-439, 2010.
27. Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, Trouillas J, and Raverot G: New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 15: 37-43, 2012.
28. Zeng J, See AP, Aziz K, Thiyagarajan S, Salih T, Gajula RP, Armour M, Phallen J, Terezakis S, Kleinberg L, Redmond K, Hales RK, Salvatori R, Quinones-Hinojosa A, Tran PT and Lim M: Nelfinavir induces radiation sensitization in pituitary adenoma cells. Cancer Biol Ther 12: 657-663, 2011.
29. Zhang H, Zhang G, Gonzalez FJ, Park SM and Cai D: Hypoxiainducible factor directs POMC gene to mediate hypothalamic glucose sensing and energy balance regulation. PLoS Biol 9: e1001112, 2011.
30. Zoncu R, Efeyan A and Sabatini DM: mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Revi Mol Cell Biol 12: 21-35, 2011.